51 related articles for article (PubMed ID: 24993178)
1. Inhibition of activated Ras suppresses multiple oncogenic Hub genes in human epithelial tumors.
Cao L; Wang P; Luo H; Wang XR; Wang XF; Zhang JX; Wang YY; Yao L; Liu N; You YP
Int J Oncol; 2014 Oct; 45(4):1609-17. PubMed ID: 24993178
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic RAS alters the global and gene-specific histone modification pattern during epithelial-mesenchymal transition in colorectal carcinoma cells.
Peláez IM; Kalogeropoulou M; Ferraro A; Voulgari A; Pankotai T; Boros I; Pintzas A
Int J Biochem Cell Biol; 2010 Jun; 42(6):911-20. PubMed ID: 20109579
[TBL] [Abstract][Full Text] [Related]
3. In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis.
Qian J; Niu J; Li M; Chiao PJ; Tsao MS
Cancer Res; 2005 Jun; 65(12):5045-53. PubMed ID: 15958547
[TBL] [Abstract][Full Text] [Related]
4. Interruption of β-catenin suppresses the EGFR pathway by blocking multiple oncogenic targets in human glioma cells.
Yue X; Lan F; Yang W; Yang Y; Han L; Zhang A; Liu J; Zeng H; Jiang T; Pu P; Kang C
Brain Res; 2010 Dec; 1366():27-37. PubMed ID: 20969832
[TBL] [Abstract][Full Text] [Related]
5. Depletion of ERK2 but not ERK1 abrogates oncogenic Ras-induced senescence.
Shin J; Yang J; Lee JC; Baek KH
Cell Signal; 2013 Dec; 25(12):2540-7. PubMed ID: 23993963
[TBL] [Abstract][Full Text] [Related]
6. Restoration of IRF1-dependent anticancer effects by MEK inhibition in human cancer cells.
AbuSara N; Razavi S; Derwish L; Komatsu Y; Licursi M; Hirasawa K
Cancer Lett; 2015 Feb; 357(2):575-81. PubMed ID: 25497010
[TBL] [Abstract][Full Text] [Related]
7. ERβ regulates NSCLC phenotypes by controlling oncogenic RAS signaling.
Nikolos F; Thomas C; Rajapaksa G; Bado I; Gustafsson JÅ
Mol Cancer Res; 2014 Jun; 12(6):843-54. PubMed ID: 24618619
[TBL] [Abstract][Full Text] [Related]
8. c-Myc inhibits Ras-mediated differentiation of pheochromocytoma cells by blocking c-Jun up-regulation.
Vaqué JP; Fernández-García B; García-Sanz P; Ferrandiz N; Bretones G; Calvo F; Crespo P; Marín MC; León J
Mol Cancer Res; 2008 Feb; 6(2):325-39. PubMed ID: 18314492
[TBL] [Abstract][Full Text] [Related]
9. Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras.
Kim SH; Nakagawa H; Navaraj A; Naomoto Y; Klein-Szanto AJ; Rustgi AK; El-Deiry WS
Cancer Res; 2006 Nov; 66(21):10415-24. PubMed ID: 17079462
[TBL] [Abstract][Full Text] [Related]
10. Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest.
Yaari S; Jacob-Hirsch J; Amariglio N; Haklai R; Rechavi G; Kloog Y
Clin Cancer Res; 2005 Jun; 11(12):4321-30. PubMed ID: 15958613
[TBL] [Abstract][Full Text] [Related]
11. A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation.
Bazarov AV; Adachi S; Li SF; Mateyak MK; Wei S; Sedivy JM
Cancer Res; 2001 Feb; 61(3):1178-86. PubMed ID: 11221849
[TBL] [Abstract][Full Text] [Related]
12. Kos1, a nonreceptor tyrosine kinase that suppresses Ras signaling.
Hoare K; Hoare S; Smith OM; Kalmaz G; Small D; Stratford May W
Oncogene; 2003 Jun; 22(23):3562-77. PubMed ID: 12789265
[TBL] [Abstract][Full Text] [Related]
13. Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation.
Konishi H; Karakas B; Abukhdeir AM; Lauring J; Gustin JP; Garay JP; Konishi Y; Gallmeier E; Bachman KE; Park BH
Cancer Res; 2007 Sep; 67(18):8460-7. PubMed ID: 17875684
[TBL] [Abstract][Full Text] [Related]
14. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic Ras/Her-2 mediate hyperproliferation of polarized epithelial cells in 3D cultures and rapid tumor growth via the PI3K pathway.
Janda E; Litos G; Grünert S; Downward J; Beug H
Oncogene; 2002 Aug; 21(33):5148-59. PubMed ID: 12140765
[TBL] [Abstract][Full Text] [Related]
16. Differential anti-tumor activities of curcumin against Ras- and Src-activated human adenocarcinoma cells.
Ono M; Higuchi T; Takeshima M; Chen C; Nakano S
Biochem Biophys Res Commun; 2013 Jun; 436(2):186-91. PubMed ID: 23726918
[TBL] [Abstract][Full Text] [Related]
17. Activated Ras enhances insulin-like growth factor I induction of vascular endothelial growth factor in prostate epithelial cells.
Stearns M; Tran J; Francis MK; Zhang H; Sell C
Cancer Res; 2005 Mar; 65(6):2085-8. PubMed ID: 15781617
[TBL] [Abstract][Full Text] [Related]
18. Activated Ras induces lens epithelial cell hyperplasia but not premature differentiation.
Reneker LW; Xie L; Xu L; Govindarajan V; Overbeek PA
Int J Dev Biol; 2004; 48(8-9):879-88. PubMed ID: 15558479
[TBL] [Abstract][Full Text] [Related]
19. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
20. A dominant role for the c-Jun NH2-terminal kinase in oncogenic ras-induced morphologic transformation of human lung carcinoma cells.
Xiao L; Lang W
Cancer Res; 2000 Jan; 60(2):400-8. PubMed ID: 10667594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
